Clinical Update
Published August 10, 2026
SS-31 Elamipretide: 2026 Mitochondrial Peptide Research
SS-31 (elamipretide), a mitochondrial-targeting tetrapeptide, has advanced significantly in clinical development. This article reviews elamipretide's mechanism, recent 2026 clinical trial updates, and its therapeutic applications across mitochondrial disorders.
What is SS-31?
SS-31 is a small, mitochondria-penetrating tetrapeptide designed to stabilize cardiolipin, a critical phospholipid in the inner mitochondrial membrane. Cardiolipin dysfunction is implicated in multiple mitochondrial disorders, and SS-31's mechanism is to restore its function, improving ATP production and reducing reactive oxygen species (ROS) production. The peptide crosses the outer mitochondrial membrane through a specific transporter.
2026 regulatory milestone: FDA approval
FORZINITYâ„¢ (elamipretide) received FDA approval for Barth syndrome, a rare genetic mitochondrial disorder. This represents the first FDA-approved mitochondrial-targeting peptide therapeutic, a significant validation of the mechanism and clinical benefit.
2026 clinical trial progress
Multiple Phase 2 and Phase 3 trials are underway or completed for various indications:
- Barth Syndrome (NuPOWER trial). Fully enrolled as of May 2026. This rare X-linked disorder is characterized by cardiolipin remodeling defects.
- Primary Mitochondrial Myopathy (Phase 2, March 2026 data). A 43-patient trial showed a mean 31% increase in ATP production in muscle biopsies and 67% of patients reported subjective improvement in exercise tolerance.
- Heart Failure with Preserved Ejection Fraction (HFpEF). Phase 2 studies ongoing, exploring elamipretide's cardioprotective properties.
- Acute Kidney Injury (AKI). Renal mitochondrial dysfunction is being targeted in Phase 2 trials.
Preclinical mechanistic insights (January 2026)
A study published in Cell Metabolism (January 2026) in aged mice demonstrated that elamipretide treatment:
- Restored mitochondrial fission-fusion dynamics. Aging impairs the balance between mitochondrial division (fission) and fusion, leading to mitochondrial dysfunction. Elamipretide restored normal dynamics.
- Increased mitophagy by 42%. Mitophagy (selective autophagy of damaged mitochondria) is a critical quality-control process; improved mitophagy flux removes dysfunctional mitochondria.
Therapeutic potential and research directions
SS-31's success opens new avenues for mitochondrial medicine:
- Rare genetic mitochondrial diseases (confirmed via FORZINITY approval).
- Aging-related mitochondrial decline and frailty.
- Metabolic dysfunction and metabolic syndrome.
- Cardiovascular and renal diseases involving mitochondrial stress.
Research use only. All products referenced are intended for in-vitro laboratory research only and are not for human or animal consumption. You must be 21+ to purchase. This article is educational and is not medical advice; no safety, efficacy or treatment claim is made about any product.
Research peptides
We supply high-purity research peptides for preclinical and mitochondrial biology research:
View research peptides
Sources & further reading
Universe Peptide publishes research-focused education for the scientific community. Products are for laboratory research only. See more in our News & research updates.